Document text
Principal Investigator: REX L CHISHOLM
Organization: NORTHWESTERN UNIVERSITY AT CHICAGO
Fiscal Year: 2020
Award: $384,018
Funding agency: National Human Genome Research Institute
PROJECT SUMMARY
Since early 2020, COVID-19 disease spread rapidly across the US and will likely be sustained or recur
periodically until an effective vaccine or prophylactic treatment is developed. The pandemic will have a large
impact on the conduct of the next phase of eMERGE, including recruitment of new participants as well as
development, validation, and implementation of genomic risk assessments based on polygenic risk scores
(PRS). The supplement presents an opportunity for Northwestern to contribute eMERGE network efforts to
promote the understanding of the genetic epidemiology and individual susceptibility to COVID-19 infection,
disease severity, and complications. In support of efforts proposed in the supplement application for the
coordinating center, we propose to expand Aim 1 of our eMERGE 4 application with the following aim: Create,
validate and implement COVID-19 ePhenotyping for manifest disease, disease severity, and specific
COVID-19 complications in the Northwestern biobank. Recognizing that decisions about ePhenotype
development and implementation will be made in collaboration with the coordinating center and other
participating eMERGE 4 sites, in this supplement, we propose leading phenotype development of three critical
COVID-19 phenotypes 1) myocarditis, 2) acute kidney injury, and 3) coagulopathy complications. Additionally,
we propose to facilitate studies of the full spectrum of COVID-19 disease including those with minimal or no
symptoms, which will motivate participation in eMERGE 4 among individuals who may have been at higher risk
to exposure to COVID-19. To achieve this, we will expand aim 2 of our parent eMERGE 4 application with the
following 2 aims: a) provide SARS-CoV-2 serological testing for IgG to all Northwestern participants
recruited into eMERGE 4 in year 1 of the award and b) facilitate SARS-CoV-2 serology testing and
genotyping of cohabitating family members of eMERGE 4 participants by mail.
Terms: <2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Acute Renal Failure with Renal Papillary Necrosis><Assay><Award><Bioassay><Biologic Assays><Biological Assay><Blood><Blood Coagulation Disorders><Blood Reticuloendothelial System><COVID-19><COVID19><Clinical Data><Coagulation Disorder><Coagulopathy><Collaborations><Data Banks><Databanks><Development><Disease><Disorder><ELISA><Electronic Medical Records and Genomics Network><Enzyme-Linked Immunosorbent Assay><Exposure to><Family><Family member><Genetic analyses><Genetic study><Genomics><Genotype><Household><IgG><Immunoglobulin G><Incidence><Individual><Infection><Institution><Investigators><Knowledge><Measures><Myocarditis><Parents><Participant><Patient Recruitments><Phase><Phenotype><Predisposition><Prophylactic treatment><Prophylaxis><Research Personnel><Researchers><Risk Assessment><Risk Management><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Serologic tests><Serological Tests><Severe acute respiratory syndrome coronavirus 2><Severities><Severity of illness><Site><Spottings><Susceptibility><Symptoms><Testing><Transmission><Vaccines><Validation><Work><Wuhan coronavirus><acute kidney injury><base><biobank><biorepository><bleeding disorder><cardiac inflammation><clotting disorder><corona virus disease 2019><coronavirus disease 2019><data depository><data repository><data warehouse><developmental><disease severity><eMERGE Consortium><eMERGE Network><genetic analysis><genetic epidemiologic study><genetic epidemiology><high risk><pandemic><pandemic disease><participant recruitment><polygenic risk score><programs><receptor binding><receptor bound><recruit><serology><transmission process>